Navigation Links
VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Date:9/15/2008

y: Tilmann M Brotz, Ph.D., Vice President of Pre-Clinical

Research and Development, VIA Pharmaceuticals

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
(Date:7/22/2014)... July 22, 2014 Get Real ... Immune Deficiency Foundation (IDF) to provide their ... that will allow them to electronically track their symptoms, ... their illnesses. It will also allow those patients and ... consent to have their data shared with the ...
(Date:7/22/2014)... 22, 2014 JumpSoft, Inc., a ... automated recovery at the application level, today released ... to application-centric management. , Based on ... the report provides insights, context and depth regarding ... application and system uptime. London, Ink, a B2B ...
(Date:7/22/2014)... Recently, MyDressCity.com has excitedly launched a promotion for ... all people can get a discount, up to 60% off, ... the new range; all the new items are of top ... Quinceanera gowns for worldwide clients. Our dress specialists are always ... of MyDressCity.com, “Our Quinceanera dresses are selling well in the ...
(Date:7/22/2014)... July 22, 2014 BlackBox Biometrics, Inc. ... Gauge™ System with advancements including a new ... gauges represent a functional revision of the already robust ... capture complex data on blast events by recording a ... The extreme changes in overpressure that accompany a blast ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 "The Big Secrets: ... is one of the most important books young people can read. ... It will murder some of the “truths” people have been living ... what will the new truths be? From sex to death, this ... age 16 to 21, and it tells it like it is. ...
Breaking Medicine News(10 mins):Health News:Get Real Health to Partner with Immune Deficiency Foundation 2Health News:Get Real Health to Partner with Immune Deficiency Foundation 3Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 2Health News:JumpSoft Releases Report on Shift from Infrastructure-Centric to Application-Centric IT Management 3Health News:Beautiful Dama Dresses Now Released By Popular Online Supplier MyDressCity.com 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 2Health News:BlackBox Biometrics®, Inc. continues to advance blast overpressure measurement with release of new Blast Gauge 3Health News:Strategic Book Publishing & Rights Agency Announces the Release of its Newest Title, “The Big Secrets: Ten Things Every Young Person Should Know About and Why” 2
... number of HIV cases in Africa as of last ... from the United Nations //.The World Health Organization has ... AIDS in Africa. ,The WHO has ... in healthcare in Africa could be used to give ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... replaced by a pill according to European researchers. The ... of the Grazax allergen tablet.// Hay fever and other ... ,Allergies are a result of the immune system reacting ... ,Immunotherapy is supposed to enhance tolerance of ...
... of people admitted into hospitals with diabetic related issues is ... of Health and Welfare.// ,The author of the report, ... and 2004, hospital admissions for diabetes increased by 20 per ... more people are being diagnosed with diabetes, it is increasing ...
... have found that a glass of orange juice every day ... citrus juices like lemonade. // ,The study that is ... 26 issue of the Clinical Journal of the American Society ... that all citrus fruit juices could help prevent the formation ...
... Australia are conducting a study involving 300 pairs of older ... ,'Even though we have twins that are identical, ... Sachdev said. 'By studying twins, we will be able to ... and which are environmental.' ,Prof Sachdev said that time ...
Cached Medicine News:Health News:A Glass of Orange Juice To Keep Recurrence Of Kidney Stones At Bay 2
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
The latest wave in punctum plugs! Unique design featureing reservoir indentations to reduce foreign body sensation. Elast™ - a proprietary formulated, hight performance Liquid Silicon Rubber ...
... Attain Prevail's steerable tip, along with various ... obtain the curve you need, when you ... visualization of the cardiac venous anatomy, adjust ... - Adjust curve and reach by ...
... Attain™ Deflectable Catheter - designed to be ... single catheter. Steerablility - Create a variety ... a single, steerable guide catheter. Lock the ... to address each patient's unique anatomy during ...
Medicine Products: